A comparison of HCV antibody testing in drug-free and methadone maintenance treatment programs in the United States

Shiela M. Strauss, Janetta M. Astone, Don Des Jarlais, Holly Hagan

Research output: Contribution to journalArticle

Abstract

Drug treatment programs are uniquely situated to screen patients for antibodies for hepatitis C virus (HCV), an infectious disease that has reached epidemic proportions among drug users. This paper compares the accessibility and patients' use of opportunities for HCV antibody testing in a large sample of methadone and drug-free treatment programs (N=256) in the US, and reports programs' recent changes and future plans concerning it. Results indicate that almost all methadone and about two-thirds of drug-free programs in the sample provided HCV antibody screening to at least some patients in 2001. While about two-thirds of the methadone and close to one-third of the drug-free programs offered this service to all patients, these programs report that only about 3/5 of their patients actually provided specimens for testing for HCV antibodies. Some drug treatment programs were planning to increase the availability and accessibility of HCV antibody screening, but others were planning to cut back on these services, primarily due to limited resources. These results can inform policymakers who advocate for increased HCV antibody screening in drug treatment programs about the current level and future plans for implementing these services, illuminating where resources and motivational efforts need to be targeted.

Original languageEnglish (US)
Pages (from-to)227-236
Number of pages10
JournalDrug and Alcohol Dependence
Volume73
Issue number3
DOIs
StatePublished - Mar 8 2004

Fingerprint

Hepatitis C Antibodies
Methadone
contagious disease
drug
Drug therapy
Testing
Pharmaceutical Preparations
Screening
Therapeutics
Planning
Preclinical Drug Evaluations
Virus Diseases
program planning
Drug Users
Communicable Diseases
resources
Availability
planning

Keywords

  • Drug treatment programs
  • Health services
  • Hepatitis C
  • Methadone maintenance
  • Screening

ASJC Scopus subject areas

  • Medicine(all)
  • Behavioral Neuroscience
  • Toxicology
  • Health(social science)

Cite this

A comparison of HCV antibody testing in drug-free and methadone maintenance treatment programs in the United States. / Strauss, Shiela M.; Astone, Janetta M.; Des Jarlais, Don; Hagan, Holly.

In: Drug and Alcohol Dependence, Vol. 73, No. 3, 08.03.2004, p. 227-236.

Research output: Contribution to journalArticle

@article{93b92233a95a4dae97791dbe70292559,
title = "A comparison of HCV antibody testing in drug-free and methadone maintenance treatment programs in the United States",
abstract = "Drug treatment programs are uniquely situated to screen patients for antibodies for hepatitis C virus (HCV), an infectious disease that has reached epidemic proportions among drug users. This paper compares the accessibility and patients' use of opportunities for HCV antibody testing in a large sample of methadone and drug-free treatment programs (N=256) in the US, and reports programs' recent changes and future plans concerning it. Results indicate that almost all methadone and about two-thirds of drug-free programs in the sample provided HCV antibody screening to at least some patients in 2001. While about two-thirds of the methadone and close to one-third of the drug-free programs offered this service to all patients, these programs report that only about 3/5 of their patients actually provided specimens for testing for HCV antibodies. Some drug treatment programs were planning to increase the availability and accessibility of HCV antibody screening, but others were planning to cut back on these services, primarily due to limited resources. These results can inform policymakers who advocate for increased HCV antibody screening in drug treatment programs about the current level and future plans for implementing these services, illuminating where resources and motivational efforts need to be targeted.",
keywords = "Drug treatment programs, Health services, Hepatitis C, Methadone maintenance, Screening",
author = "Strauss, {Shiela M.} and Astone, {Janetta M.} and {Des Jarlais}, Don and Holly Hagan",
year = "2004",
month = "3",
day = "8",
doi = "10.1016/j.drugalcdep.2003.08.009",
language = "English (US)",
volume = "73",
pages = "227--236",
journal = "Drug and Alcohol Dependence",
issn = "0376-8716",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - A comparison of HCV antibody testing in drug-free and methadone maintenance treatment programs in the United States

AU - Strauss, Shiela M.

AU - Astone, Janetta M.

AU - Des Jarlais, Don

AU - Hagan, Holly

PY - 2004/3/8

Y1 - 2004/3/8

N2 - Drug treatment programs are uniquely situated to screen patients for antibodies for hepatitis C virus (HCV), an infectious disease that has reached epidemic proportions among drug users. This paper compares the accessibility and patients' use of opportunities for HCV antibody testing in a large sample of methadone and drug-free treatment programs (N=256) in the US, and reports programs' recent changes and future plans concerning it. Results indicate that almost all methadone and about two-thirds of drug-free programs in the sample provided HCV antibody screening to at least some patients in 2001. While about two-thirds of the methadone and close to one-third of the drug-free programs offered this service to all patients, these programs report that only about 3/5 of their patients actually provided specimens for testing for HCV antibodies. Some drug treatment programs were planning to increase the availability and accessibility of HCV antibody screening, but others were planning to cut back on these services, primarily due to limited resources. These results can inform policymakers who advocate for increased HCV antibody screening in drug treatment programs about the current level and future plans for implementing these services, illuminating where resources and motivational efforts need to be targeted.

AB - Drug treatment programs are uniquely situated to screen patients for antibodies for hepatitis C virus (HCV), an infectious disease that has reached epidemic proportions among drug users. This paper compares the accessibility and patients' use of opportunities for HCV antibody testing in a large sample of methadone and drug-free treatment programs (N=256) in the US, and reports programs' recent changes and future plans concerning it. Results indicate that almost all methadone and about two-thirds of drug-free programs in the sample provided HCV antibody screening to at least some patients in 2001. While about two-thirds of the methadone and close to one-third of the drug-free programs offered this service to all patients, these programs report that only about 3/5 of their patients actually provided specimens for testing for HCV antibodies. Some drug treatment programs were planning to increase the availability and accessibility of HCV antibody screening, but others were planning to cut back on these services, primarily due to limited resources. These results can inform policymakers who advocate for increased HCV antibody screening in drug treatment programs about the current level and future plans for implementing these services, illuminating where resources and motivational efforts need to be targeted.

KW - Drug treatment programs

KW - Health services

KW - Hepatitis C

KW - Methadone maintenance

KW - Screening

UR - http://www.scopus.com/inward/record.url?scp=1242314709&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1242314709&partnerID=8YFLogxK

U2 - 10.1016/j.drugalcdep.2003.08.009

DO - 10.1016/j.drugalcdep.2003.08.009

M3 - Article

VL - 73

SP - 227

EP - 236

JO - Drug and Alcohol Dependence

JF - Drug and Alcohol Dependence

SN - 0376-8716

IS - 3

ER -